Charlot Biosciences cellPhoresis

Brand Heritage and Innovation

Charlot Biosciences (often referred to as CBio) was founded in 2016 by Dr. David Charlot. The brand originated from advanced research in biophysics and engineering, specifically focusing on how to analyze living cells without destroying them. Dr. Charlot’s background, spanning institutions like UCLA and ASU, led to the development of the proprietary cellPhoresis technology, which uses dielectrophoresis and microfluidics to identify and sort cells based on their unique electrical signatures.

Manufacturing and Operations

As a high-tech biotechnology firm, Charlot Biosciences operates primarily out of the United States. Its corporate headquarters are located in Tampa, Florida, with significant research and development roots tied to the California NanoSystems Institute (CNSI) at UCLA and University of California, Irvine. The company’s manufacturing of specialized laboratory devices and sensors is centered in the U.S. to ensure quality control for sensitive defense and pharmaceutical applications.

Ownership and Market Position

Charlot Biosciences remains a privately held, independent minority-owned small business. The brand has achieved growth primarily through non-dilutive government funding, including grants from the Department of Defense (DOD), the United States Air Force (USAF), and the Coalition for Epidemic Preparedness Innovations (CEPI). This funding supports the commercialization of their technology for vaccine sterility testing, gene therapy quality control, and rapid pathogen detection.